Valuation: PTC Therapeutics, Inc.

Market Cap 6.52B 5.7B 5.26B 4.85B 9.13B 628B 9.34B 62.83B 24.71B 307B 24.48B 23.94B 1,058B P/E 2026 *
108x
P/E 2027 * 29.8x
Enterprise Value 4.84B 4.23B 3.9B 3.6B 6.78B 466B 6.93B 46.63B 18.34B 228B 18.17B 17.77B 786B EV / Sales 2026 *
4.1x
EV / Sales 2027 * 3.57x
Free-Float
92.62%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 54 21/03/2023
Director of Finance/CFO 41 12/07/2023
Chief Tech/Sci/R&D Officer - 30/09/2017
Director TitleAgeSince
Chairman 74 31/10/2004
Chairman 80 30/03/1998
Director/Board Member 65 30/11/2005
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 6.52B
+0.85%-0.80%+52.79%+161.33% 1,051B
+1.23%-1.53%+54.58%+59.08% 609B
+0.04%+2.58%+34.47%+86.33% 450B
+0.78%-0.71%+29.28%+24.10% 330B
+1.41%+0.58%+35.44%+40.67% 284B
-0.27%-1.87%+22.34%+22.51% 263B
-1.76%+2.37%-20.43%-38.00% 223B
-1.42%+0.80%+24.27%+57.50% 198B
-1.48%+3.43%+24.08%+71.67% 167B
Average -0.06%+0.54%+28.54%+53.91% 397.23B
Weighted average by Cap. +0.37%+0.02%+37.51%+79.63%

Financials

2026 *2027 *
Net sales 1.18B 1.03B 951M 876M 1.65B 114B 1.69B 11.36B 4.47B 55.61B 4.43B 4.33B 191B 1.34B 1.17B 1.08B 998M 1.88B 129B 1.92B 12.94B 5.09B 63.34B 5.04B 4.93B 218B
Net income 53.05M 46.36M 42.78M 39.43M 74.33M 5.11B 75.98M 511M 201M 2.5B 199M 195M 8.61B 195M 170M 157M 145M 273M 18.74B 279M 1.88B 738M 9.18B 731M 715M 31.59B
Net Debt -1.68B -1.47B -1.36B -1.25B -2.35B -162B -2.41B -16.2B -6.37B -79.27B -6.31B -6.17B -273B -1.73B -1.51B -1.39B -1.28B -2.42B -166B -2.47B -16.65B -6.55B -81.47B -6.49B -6.35B -280B
Logo PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
78.59USD
Average target price
95.93USD
Spread / Average Target
+22.06%

Quarterly revenue - Rate of surprise